Scios/Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Firms will begin a 20-patient pilot study this quarter at Karolinska Hospital in Sweden to evaluate hemodynamic and clinical effects of Scios' Natrecor investigational drug using information collected by Medtronic's Chronicle implantable hemodynamic monitor during and after infusions. Scios' amended new drug application was filed in January. Medtronic plans to file a PMA for the Chronicle by year-end